“Before Theranos became infamous medical company, it was a small startup that was looking for funds for development,” writes Axios. Edition managed to get the presentation Theranos that the user showed to potential investors in 2006. One of the things that distinguishes the Axios editorial Board, judging by the presentation, Theranos initially did not plan to enter the consumer market, and was going to work only with pharmaceutical companies. In 2006 the company planned to raise $30 million in the IPO. In the opinion of the project team, the analysis technology of blood Theranos could help to involve more patients in the testing of medicines and faster to withdraw such drugs on the market.
Tests that claimed employees could carry over no more than 30 minutes. This speed would allow, for example, to adjust the amount of the drug in the patients blood. The companys management stressed that the developed technique allowed to test in all conditions — and to do so could anyone. The blood test can be carried out arbitrarily often. In 2006, the company had 50 employees.